About the company
Amgen, a renowned biotechnology company, has established itself as a leader in the development of biotechnology-based human therapeutics. With a strong focus on renal disease and cancer supportive care products, Amgen has revolutionized the field of medicine with its groundbreaking discoveries and life-saving drugs. Among their flagship drugs are Epogen and Aranesp, which are red blood cell boosters used to treat anemia in patients undergoing dialysis. These drugs have immensely improved the quality of life for individuals suffering from chronic kidney disease. Amgen is also a pioneer in immune system boosters, offering Neupogen and Neulasta. These medications work by stimulating the production of white blood cells, helping patients undergoing chemotherapy to recover faster and reduce the risk of infections. In the field of inflammatory diseases, Amgen has introduced two highly effective medications, Enbrel and Otezla. Enbrel, a tumor necrosis factor (TNF) inhibitor, provides relief to patients suffering from rheumatoid arthritis, psoriasis, and other autoimmune disorders. Otezla, on the other hand, is an oral medication used to treat psoriasis and psoriatic arthritis. With a focus on treating cancer, Amgen introduced Vectibix in 2006, a monoclonal antibody therapy for the treatment of colorectal cancer. This marked a significant milestone for the company, as it ventured into the field of oncology. Amgen's commitment to bone health is evident in the development of Prolia/Xgeva, a medication approved in 2010. Prolia is used to treat osteoporosis in postmenopausal women, while Xgeva is specifically designed to prevent fractures and bone complications in patients with bone metastases. In 2019, Amgen launched Evenity, a breakthrough drug for the treatment of osteoporosis in postmenopausal women at high risk of fracture. This medication helps to strengthen bones and reduce the incidence of fractures. The acquisition of Onyx Pharmaceuticals in 2013 further enhanced Amgen's presence in the field of oncology. Through this acquisition, Amgen gained access to Kyprolis, a targeted therapy for multiple myeloma. Kyprolis has provided new hope for patients battling this aggressive form of blood cancer. Continuing their dedication to innovation, Amgen has recently launched several groundbreaking drugs. Repatha, a cholesterol-lowering medication, offers an alternative treatment for patients with high cholesterol who have not adequately responded to other therapies. Aimovig, another notable addition to Amgen's portfolio, is the first and only FDA-approved medication for the preventive treatment of migraines in adults. Aimovig has presented migraine sufferers with a potential solution to reduce the frequency and severity of their debilitating attacks. Lumakras, a drug approved for the treatment of a specific type of non-small cell lung cancer, has given new hope to patients who previously had limited treatment options. Its targeted approach helps combat the disease with greater precision. Amgen also ventured into the field of respiratory diseases with Tezspire, a medication used to treat severe asthma. Tezspire has proved to be a valuable addition in the battle against this chronic and potentially life-threatening condition. In addition to these innovative developments, Amgen also focuses on biosimilars, offering affordable alternatives to some of the most critical biologic drugs in the market. The company's biosimilar portfolio includes Mvasi, a biosimilar to the widely used cancer medication Avastin, Kanjinti, a biosimilar to the breast cancer treatment Herceptin, and Amjevita, a biosimilar to the anti-inflammatory drug Humira. These biosimilars have the potential to significantly reduce healthcare costs and improve patient access to essential treatments. Amgen's relentless dedication to scientific research and development has positioned it at the forefront of the biotechnology industry. With its vast array of life-saving drugs, the company continues to shape the future of medicine and provide hope and healing to countless patients worldwide.
Website: https://www.amgen.com
Data updated: June 2, 2026
